NLS Pharmaceutics Ltd. Takes Significant Steps with Merger and Share Restructuring
NLS Pharmaceutics Ltd. (NASDAQ: NLSP) is making waves in the biopharmaceutical industry with its latest strategic initiatives. This Swiss-based company, which specializes in developing innovative therapies for central nervous system disorders, has announced its plans for a reverse share split at a ratio of 1-for-10. This step signifies a crucial restructuring intended to enhance the company’s standing in the competitive market, especially in light of its proposed merger with Kadimastem Ltd.
Details of the Reverse Split and Name Change
The reverse share split entails a reduction in the number of shares held by existing shareholders, while simultaneously increasing the share value. This transformation is set to take effect across its common shares with a par value of CHF 0.03. Upon completion of the reverse split, NLS Pharmaceutics intends to trade under the new name, NewcelX Ltd., marking a fresh chapter in its operations. This change aligns with the anticipated merger with Kadimastem, a company recognized for developing innovative therapies in neurodegenerative conditions.
Market Impact and Future Operations
Come the anticipated market opening, NLS Pharmaceutics’ shares will begin trading on the Nasdaq Capital Market under the new ticker symbol “NCEL”. This strategic move aims to better reflect the company’s evolving business model following the merger with Kadimastem Ltd. The implications of this merger are far-reaching, as the industry anticipates synergistic benefits arising from the combined expertise of both companies in the biopharmaceutical field.
New Capital Structure and Share Metrics
Post-merger, NLS Pharmaceutics aims to achieve a robust capital structure, which includes a total of 5,533,183 common shares and 124,993 preferred shares. The adjustments also encompass comprehensive plans to manage capital expansion efficiently. With consolidated efforts, the registered capital is set to empower the company’s strategic direction and enhance shareholder value.
Management Insights and Shareholder Assurance
The management of NLS has expressed confidence that this reverse share split and subsequent merger will position the company favorably for future growth and success. Importantly, shareholders can rest assured that their percentage ownership and voting rights will be preserved, with only nominal effects arising from the split. This is to ensure that the company continues to operate with transparency and aligns with the expectations of its valued investors.
Engaging with Stakeholders and Future Communications
NLS Pharmaceutics will engage VStock Transfer, LLC, as the designated exchange agent to address any inquiries regarding the reverse split and shareholder impacts. Investors and interested parties can reach out for more information, ensuring open communication during this transformative period for the company.
Continued Commitment to Innovation
NLS Pharmaceutics Ltd. remains steadfast in its commitment to driving innovation in the biopharmaceutical sector. The collaboration with Kadimastem emphasizes the shared vision to advance medical therapies, especially focusing on remedies for central nervous system disorders. This merger signifies a crucial step forward in attaining ambitious goals in therapy development and market reach.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. is dedicated to pioneering solutions for challenging health issues. With a concentrated portfolio of drugs targeting rare disorders, the company continues to push boundaries in medical science, striving for excellence in patient care through groundbreaking therapies.
Frequently Asked Questions
What is the purpose of the reverse share split?
The reverse share split aims to increase the share price, improve stock market stability, and prepare for the merger with Kadimastem.
When will the reverse split take effect?
The reverse split is scheduled to take effect on October 30, 2025, in Switzerland, and will reflect on Nasdaq the following market day.
How many shares will be outstanding after the merger?
Following the reverse split and merger, approximately 4,558,378 total outstanding common shares are projected.
What is the new name of NLS Pharmaceutics post-split?
Post-split, NLS Pharmaceutics will be known as NewcelX Ltd., effectively rebranding the company to align with its future directions.
Who acts as the exchange agent for the reverse split?
VStock Transfer, LLC has been appointed as the exchange agent to manage the processes related to the reverse share split and provide shareholder support.
